<?xml version="1.0" encoding="UTF-8"?>
<p>Two additional vaccine candidates are in phase 3 clinical trials. Both candidates (NIAID's (formulations TV003 and TV005) and Takeda's candidate contain epitopes for B and T-cell responses against DENV; therefore, the scientific community hopes good results after efficacy trials. However, up to date, the duration and maturation of the immune response elicited by both vaccine candidates is completely unknown and therefore, booster doses could be potentially required. However, booster doses with the same vaccine candidate could be inefficient, as it has been demonstrated with BCG vaccine (
 <xref rid="B49" ref-type="bibr">49</xref>) and even with the NIAID's vaccine candidate (
 <xref rid="B87" ref-type="bibr">87</xref>).
</p>
